On Day 1 of the ASH 2018 Annual Meeting, IsoPlexis presented “Single-cell multiplex proteomics reveals synergistic impact of antigen and rimiducid-dependent stimulatory signals on promoting polyfunctional GoCAR-T cells targeting prostate stem cell antigen (PSCA)”. The presentation highlighted how IsoCode Chip, IsoPlexis’ core technology developed to detect cellular responses at the single-cell level, was used to assess functional response to prostate stem cell antigen (PSCA) with Bellicum’s proprietary GoCAR-T products targeting PSCA-expressing solid tumors. The single-cell polyfunctional metrics may provide insights into quality check of pre-infusion CAR-T cell products and potential biomarker discovery to predict efficacy, persistence and safety of CAR-T cell therapy in solid tumor. ASH is a leading conference in hematology where clinicians and researchers deliver the latest breakthroughs across blood-related diseases.
December 9, 2017
Min. Read121 words